Company

Product

Description

Indication

Status


Abbvie Inc., of North Chicago

Rinvoq (upadacitinib)

Oral JAK inhibitor

Moderate to severe rheumatoid arthritis

Approved by FDA for use in adults who have inadequate response or intolerance to methotrexate

Celgene Corp., of Summit, N.J.

Inrebic (fedratinib)

JAK2 inhibitor

Myelofibrosis

Approved by FDA for use in adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) disease

Gilead Sciences Inc., of Foster City, Calif.

Filgotinib

Oral, selective JAK1 inhibitor

Rheumatoid arthritis

Marketing application has been validated and is under review by the EMA

Nabriva Therapeutics plc, of Dublin

Contepo (fosfomycin)

Antibiotic

Complicated urinary tract infections, including acute pyelonephritis 

After reviewing notes from FDA meeting, company plans to submit for approval early in the fourth quarter of this year


Notes

For more information about individual companies and/or products, see Cortellis.

No Comments